Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Cloxazolam→

Cloxazolam Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
24166-13-0
Molecular formula
C17H14Cl2N2O2
Molecular weight
349.2 g/mol
Drug class
Benzodiazepine anxiolyticpositive allosteric modulator of GABAA receptors
Mechanism of action
Enhances GABA-mediated inhibitory neurotransmission through positive allosteric modulation of GABAA receptor complexes at the benzodiazepine binding site, producing anxiolytic and sedative effects.
Indications / reported uses
  • Short-term treatment of anxiety disorders in countries where cloxazolam products are authorised; duration should be limited because of tolerance, dependence and withdrawal risk

Sources: NLM MeSH — Cloxazolam · PubMed — Cloxazolam benzodiazepine pharmacology · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Cloxazolam Environmental Risk Assessment (ERA) (the Cloxazolam ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.